Cognitive deficits seen in COVID-19 patients regardless of symptom duration
Feb 29, 2024
Compared with those without COVID-19, similar deficits were seen for those in whom symptoms resolved in less than four or at least 12 weeks.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Cognitive symptoms common with post-COVID-19 condition
Feb 15, 2024
Symptoms were linked to increased odds of at least moderate interference with functioning and lower odds of full-time employment.
Prolonged SARS-CoV-2 risk varies across immunosuppressive conditions
Jan 31, 2024
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
Simnotrelvir shortens time to resolution of symptoms in COVID-19
Jan 18, 2024
On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group versus the placebo group.
Updated immunization schedule presented for adults for 2024
Jan 11, 2024
The changes include a recommendation for all adults to receive a dose of the new COVID-19 vaccine and RSV vaccination.
Bivalent COVID-19 shot effective for preventing thromboembolic events
Jan 11, 2024
The findings were seen for adults aged 65 years and older and for those aged 18 years and older with end-stage renal disease.
Virologic rebound occurs in ~20 percent receiving nirmatrelvir-nitonavir
Nov 14, 2023
Virologic rebound was more common among those who started therapy within two days of symptom onset.
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.